Sells it 100%, $10.1B a year“Our robotic-assisted platforms extend the care teams’ capabilities to deliver minimally invasive care.”
Latest 10-KFY2025 ·
Intuitive Surgical delivered broad-based FY2025 growth as rising procedure volumes expanded recurring revenue and da Vinci 5 accelerated system placements. Revenue increased 21% and operating income increased 25%, despite lower gross margins from tariffs, new-system costs, manufacturing expansion, and service repairs. The investment case rests on converting a larger installed base into sustained…
da Vinci antitrust settlement drives a $450M charge and GAAP profit decline despite procedure and lease growth
Latest 8-KGovernance change ·
Bylaws tighten shareholder nomination and proxy rules; non-director-election actions shift to majority of votes cast, excluding abstentions and broker non-votes.
Latest 8-KBuybackExecutive payShareholder vote ·
Board expands buyback authorization to $5.0B; stockholders extend the incentive plan and increase its share reserve.
Latest 8-KPositiveDeal completed ·
Acquisition of da Vinci and Ion distributors expands direct operations in Italy, Spain and Portugal.
Sells it, part of MedTech“This portfolio includes instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies designed to support procedural consistency and efficiency across multiple surgical specialties.”
Latest 10-KFY2025 ·
DARZALEX and CARVYKTI growth offset STELARA’s biosimilar-driven decline; a talc reserve reversal boosted earnings without lifting operating cash flow.
Sells it, part of Ortho Tech“Stryker created Ortho Tech in Q1 2026, combining Orthopaedic Instruments with Mako and enabling technologies; Neuro Cranial and spine enabling technologies were aligned with the remaining Instruments business, and historical segment information was recast.”